Entera Bio Ltd. EV/FCF

EV/FCF of ENTX for past 10 years: annual, quarterly and twelve month trailing (TTM) including EV/FCF growth rates and interactive chart. A valuation metric that measures the enterprise value of a stock compared to its free cash flow. Free cash flow is calculated as operating cash flow - capital expenditures and is a more accurate measure of a company's earning power than net income, as it's not easily manipulated. A low EV/FCF ratio can indicate undervaluation, while a high one might mean the growth expectations around the company are elevated. EV/FCF ratio can be compared to different companies in the same industry or to a company’s own historical valuation.

Highlights and Quick Summary

Current EV/FCF of Entera Bio Ltd. is -1.22 (as of December 30, 2019)
  • EV/FCF for the quarter ending June 29, 2020 was -2.15 (a -12.92% decrease compared to previous quarter)
  • Year-over-year quarterly EV/FCF decreased by -27.99%
  • Annual EV/FCF for 2019 was -1.22 (a -70.08% decrease from previous year)
Visit stockrow.com/ENTX for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EV/FCF of Entera Bio Ltd.

Most recent EV/FCFof ENTX including historical data for past 10 years.

Interactive Chart of EV/FCF of Entera Bio Ltd.

Entera Bio Ltd. EV/FCF for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 -2.15 -2.47
2019 -1.22 -2.99 -3.76 -1.22
2018 -4.08 -4.08

Business Profile of Entera Bio Ltd.

Sector: Medical
Industry: Drugs
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union fractures. The company was founded in 2010 and is headquartered in Jerusalem, Israel.